期刊
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
卷 8, 期 2, 页码 280-289出版社
AMER SOC NEPHROLOGY
DOI: 10.2215/CJN.08230811
关键词
-
资金
- Vifor Pharma
- Vffor International Inc.
- St. Gallen, Switzerland
- Genzyme
- Shire
Background and objectives A dose-finding study was undertaken to investigate the efficacy of PA21, a novel polynuclear iron(III)-oxyhydroxide phosphate binder. Design, setting, participants, & measurements In a randomized, active-controlled, multicenter, open-label study at 50 clinical sites in Europe and the United States, hemodialysis patients were randomized to PA21 at dosages of 1.25, 5.0, 7.5, 10.0, or 12.5 g/d or sevelamer-HCl 4.8 g/d for 6 weeks. The primary efficacy endpoint was the change in serum phosphorus concentration from baseline. Results There were 154 participants who were randomized and received the study drug. All groups except PA21 1.25 g/d showed a significant decrease in serum phosphorus. Mean decreases in serum phosphorus in PA21 10 g/d and 12.5 g/d were -2.00+/-1.71 mg/dl and -1.69+/-1.81 mg/dl, respectively. A similar decrease to sevelamer-HCl (-1.06+/-1.35 mg/dl) was seen with PA21 5.0 g/d (-1.08+/-2.12 mg/dl) and 7.5 g/d (-1.25+/-1.21 mg/d). Overall, 60.9% of participants randomized to PA21 and 57.7% randomized to sevelamer-HCl reported >= 1 adverse event. The most frequent adverse events were hypophosphatemia (18.0%) and discolored feces (11.7%) for the pooled PA21 dose groups, and diarrhea, hypophosphatemia, and hypotension (each 11.5%) for sevelamer-HCl. Discontinuation due to adverse events occurred at a similar rate in PA21-treated (21.1%) and sevelamer-HCl treated (23.1%) participants. Conclusions PA21 5-12.5 g/d significantly reduces serum phosphorus in hemodialysis patients. The 5 g/d and 7.5 g/d dosages showed similar efficacy to 4.8 g/d of sevelamer-HCl. The adverse events rate was similar for PA21 and sevelamer-HCl. Clin J Am Soc Nephrol 8: 280-289, 2013. doi: 10.2215/QN.08230811
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据